Gut-targeted interventions to complement PTH-lowering therapy
These findings highlight the potential of gut-targeted interventions to complement established parathyroid hormone-lowering strategies for improving skeletal health. Secondary hyperparathyroidism is a major contributor to skeletal fragility in chronic kidney disease, yet fracture risk remains high despite parathyroid hormone-lowering therapy.
Animal & Preclinical Data
Demonstrated in living animal models before large-scale human safety and dosing trials begin.